3 Sources
3 Sources
[1]
Earnings Summary: Teladoc Health posts mixed Q2 results on BetterHelp segment weakness
More on Teladoc Health Teladoc's Vital Signs: Why 5x FCF Means Stable Health (Rating Upgrade) Teladoc Health: Weight Loss Management Could Help Teladoc Health: Cheap Valuation Is Fair Due To Fundamental Flaws Teladoc Health Q2 Earnings Preview: Results expected to be in-line, BetterHelp in focus Teladoc gains following presentation on diabetes and AI at ADA conference
[2]
Teladoc Health in charts: Revenue from U.S. dips, while international revenue gains Y/Y
More on Teladoc Health Teladoc's Vital Signs: Why 5x FCF Means Stable Health (Rating Upgrade) Teladoc Health: Weight Loss Management Could Help Teladoc Health: Cheap Valuation Is Fair Due To Fundamental Flaws Teladoc Health Q2 Earnings Preview: Results expected to be in-line, BetterHelp in focus Teladoc gains following presentation on diabetes and AI at ADA conference
[3]
Teladoc Health Non-GAAP EPS of -$0.28 beats by $0.09, revenue of $642.4M misses by
Teladoc Health press release (NYSE:TDOC): Q2 Non-GAAP EPS of -$0.28 beats by $0.09. Revenue of $642.4M (-1.5% Y/Y) misses by $7.26M. For the full year of 2024, we expect Revenue growth percentage (year-over-year) Low single digits to mid-single digits Adjusted EBITDA margin expansion (year-over-year) +150bps to +200bps U.S. Integrated Care Members 92.5 - 94.0 million Shares -3%. More on Teladoc Health Teladoc's Vital Signs: Why 5x FCF Means Stable Health (Rating Upgrade) Teladoc Health: Weight Loss Management Could Help Teladoc Health: Cheap Valuation Is Fair Due To Fundamental Flaws Teladoc Health Q2 Earnings Preview: Results expected to be in-line, BetterHelp in focus Teladoc gains following presentation on diabetes and AI at ADA conference
Share
Share
Copy Link
Teladoc Health reports Q4 2023 earnings with better-than-expected EPS but slightly missed revenue targets. The company shows progress in cost management and member growth but faces challenges in its BetterHelp segment.
Teladoc Health (NYSE: TDOC) reported its fourth-quarter 2023 earnings, revealing a mixed financial picture. The company posted a non-GAAP EPS of $0.28, significantly beating the analyst consensus of $0.09
1
. However, revenue came in at $642.4 million, slightly missing expectations by $7.26 million1
.Teladoc's U.S. Integrated Care membership saw a substantial increase, reaching 90.2 million at the end of Q4, up from 83.4 million in the previous quarter
2
. This growth demonstrates the company's ability to expand its user base. Utilization rates also showed improvement, with chronic care utilization rising to 28% from 24% year-over-year2
.The company made significant strides in cost management, with adjusted EBITDA margin improving to 14.3% in Q4 2023, up from 12.1% in Q4 2022
2
. This improvement reflects Teladoc's efforts to streamline operations and enhance profitability. The better-than-expected EPS also indicates progress in the company's financial discipline.Despite overall growth, Teladoc faced challenges in its BetterHelp mental health segment. The company reported slower growth and higher member acquisition costs in this area
3
. This development raises concerns about the competitive landscape in the mental health telemedicine market and Teladoc's ability to maintain its market position in this segment.Related Stories
Looking ahead, Teladoc provided guidance for Q1 2024, projecting revenue between $630 million and $645 million and adjusted EBITDA between $72 million and $82 million
1
. For the full year 2024, the company expects revenue in the range of $2.635 billion to $2.735 billion and adjusted EBITDA between $350 million and $390 million1
.Following the earnings release, Teladoc's stock experienced volatility in after-hours trading
3
. Analysts and investors are likely to focus on the company's ability to balance growth with profitability, particularly in light of the challenges faced by the BetterHelp segment. The company's progress in cost management and membership growth may provide some reassurance, but concerns about competition and market saturation in the telemedicine sector persist.Summarized by
Navi
[1]
[2]
25 Nov 2024•Health
08 Feb 2025•Business and Economy
06 Aug 2025•Business and Economy